News | 11 August 2026
IOL Chemicals Q1 profit soars 90% as revenue jumps 37% & exports-pharma drive growth
Revenue from operations surged 37.1% year-on-year (YoY) to Rs. 756.3 crore in Q1 FY27
Revenue from operations surged 37.1% year-on-year (YoY) to Rs. 756.3 crore in Q1 FY27
The company reported operating revenue of Rs. 1,167 crore in Q1 FY27
The portfolio includes both oncology and non-oncology products, covering vials, lyophilised formulations, ampoules and pre-filled syringes
The investment will support Biodeal’s expansion across Asian markets while accelerating its growth across the CIS, Latin America, Africa and Europe
Evotec is eligible for milestone payments tied to the successful delivery of validated hit series for each target. The companies did not disclose financial terms
The authorisation is supported by the Phase III REMIX-1 and REMIX-2 trials,
The collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare broaden Philips’ wearable and out-of-hospital monitoring capabilities
Profit before exceptional items and tax stood at Rs. 510 million, while profit after exceptional items and tax was Rs. 507 million during the quarter.
LifeCell and Shraddha Diagnostics plan to expand their diagnostic services across state, providing clinicians and patients with access to a broader range of diagnostic capabilities
REVAHALE is the first and only LAMA currently available in India that combines once-daily dosing with nebulised administration, offering an additional treatment option for COPD patients
Revenue from operations rose 12% YoY to Rs. 554 crore
Sumitomo Pharma says the report contains assertions about its operations and accounting that are “clearly inconsistent with the facts
Beyond water quality monitoring, E-Eye can also analyse toxicants in environmental and biological samples, vegetables, food products, tea, herbal products, soil and milk
The event also celebrated healthy ageing through a vibrant fashion show featuring senior citizens, who showcased confidence, elegance, and enthusiasm
Hikal’s Pharmaceuticals business continued its recovery trajectory, contributing 58% of consolidated revenue, with revenue rising to Rs. 233 crore, a growth of 15.2% YoY
As part of the collaboration, Gland Pharma will establish a dedicated sterile manufacturing suite for APIs used in microparticle depot products at its JNPC facility in Visakhapatnam
The company posted a 25.2% increase in net profit to Rs 1,032 crore, while EBITDA rose 20% year-on-year to Rs 1,924 crore, with EBITDA margin improving 60 basis points to 21.0%
Expects strong H2 recovery on secured orders and pipeline growth
Subscribe To Our Newsletter & Stay Updated
